Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 5/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.36 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20149644 | 0.84 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3SLC6A2 | |
| SCHEMBL20070478 | 0.84 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3SLC6A2 | |
| SCHEMBL23555019 | 0.84 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3RET | |
| SCHEMBL22811911 | 0.84 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3SLC6A2 | |
| SCHEMBL20153227 | 0.80 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNB4CHRNA3RET | |
| SCHEMBL23126264 | 0.80 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNB4CHRNA3RET | |
| SCHEMBL22041916 | 0.78 | RET (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3RET | |
| SCHEMBL30359559 | 0.78 | RET (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3RET | |
| SCHEMBL20071394 | 0.77 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3SLC6A2 | |
| SCHEMBL21695480 | 0.77 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3753939-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3523301-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CHRNB2 2276/4885CHRNA4 1977/4885CHRNB4 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.